Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Micrurus frontalis venom
- Development stage
- Unknown
- Lead developer
- Fundação Ezequiel Dias
01
Overview
Micrurus frontalis venom is the crude venom of the South American coral snake *Micrurus frontalis*. It is a complex biological mixture composed primarily of neurotoxic three-finger toxins (frontoxins) and phospholipases A2 (PLA2). The venom's primary toxic mechanism is the blockade of nicotinic acetylcholine receptors at the neuromuscular junction, leading to neuromuscular blockade and muscle paralysis. In Brazil, this venom is utilized as an immunogen to hyperimmunize horses for the production of bivalent coral snake antivenom (antielapidic serum) by the Instituto Butantan and Fundação Ezequiel Dias (FUNED). It is not used as a therapeutic agent for any disease.
- Other names
- Micrurus frontalis crude venom
02
Targets
Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on Micrurus frontalis venom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Micrurus frontalis venom.